Bank OZK Has $648,000 Position in Pfizer Inc. (NYSE:PFE)

Bank OZK lowered its position in Pfizer Inc. (NYSE:PFE) by 2.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 24,424 shares of the biopharmaceutical company’s stock after selling 607 shares during the period. Bank OZK’s holdings in Pfizer were worth $648,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in PFE. Swedbank AB increased its holdings in Pfizer by 0.7% in the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after buying an additional 37,636 shares during the last quarter. Financial Advocates Investment Management increased its holdings in Pfizer by 5.5% in the third quarter. Financial Advocates Investment Management now owns 44,909 shares of the biopharmaceutical company’s stock worth $1,300,000 after buying an additional 2,361 shares during the last quarter. United Asset Strategies Inc. grew its holdings in Pfizer by 7.1% during the third quarter. United Asset Strategies Inc. now owns 32,274 shares of the biopharmaceutical company’s stock valued at $934,000 after purchasing an additional 2,141 shares during the last quarter. Reston Wealth Management LLC acquired a new position in Pfizer during the third quarter valued at approximately $83,000. Finally, Aspen Wealth Strategies LLC grew its holdings in Pfizer by 22.0% during the third quarter. Aspen Wealth Strategies LLC now owns 10,207 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 1,843 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 1.3 %

Shares of PFE stock opened at $26.43 on Friday. The stock has a market cap of $149.78 billion, a P/E ratio of 18.74, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The stock has a fifty day moving average price of $26.35 and a 200 day moving average price of $27.34. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s revenue was up 24.7% on a year-over-year basis. During the same period last year, the business earned $0.10 earnings per share. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.51%. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Citigroup lowered their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. UBS Group lowered their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Finally, Guggenheim restated a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.